



JEA BizDev Consulting Advises CSPC on Strategic Partnership with Radiance Biopharma

CLIENT SHOWCASE

February 19, 2025

On February 19, 2025, CSPC Megalith Biopharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group Limited (Stock code: 1093.HK), announced that it has entered into a development and commercialization agreement with Radiance Biopharma Inc., for SYS6005, a Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) antibody-drug conjugate (ADC), in the United States, certain countries in Europe, Canada and Australia. [JEA BizDev Consulting, LLC](#) served as lead business development and transaction advisor to CSPC on the strategic partnership.

CSPC will receive an upfront payment of US\$15 million, up to US\$150 million in potential development and regulatory milestones and up to US\$1,075 million in potential sales milestones, in addition to tiered royalties based on annual net sales.

The JEA BizDev Consulting team advising CSPC was led by [John Adamou](#), President and Managing Director.

For more information, please see CSPC's voluntary announcement [news release](#).